The Medivir case has been moving in a positive direction since our initiation of coverage in May, and especially the MIV-818 program, which has shown encouraging first-in-human results. We have also seen the restructuring savings having an impact on the cash burn, somewhat faster than we expected, why we believe the cash balance of SEK 192m at the end of Q2 finances operations into late-2020 (prev. mid-2020).